NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Quantumzyme's Next-Generation Enzyme Engineering Platform for Pharmaceutical Manufacturing
TL;DR
Quantumzyme's new enzymes give pharmaceutical manufacturers a competitive edge by reducing solvent costs and improving production efficiency.
Quantumzyme's enzyme platform uses AI modeling to enhance stability and selectivity, integrating with existing workflows to lower material and energy requirements.
Quantumzyme's technology supports sustainable pharmaceutical manufacturing by reducing waste and enabling environmentally responsible production practices.
Quantumzyme applies quantum mechanics and AI to engineer enzymes that make pharmaceutical manufacturing more efficient and eco-friendly.
Found this article helpful?
Share it with your network and spread the knowledge!
Quantumzyme's platform is a next-generation enzyme development system that creates high-performance enzymes with enhanced stability, selectivity, and compatibility with lower-cost solvents like isopropyl alcohol, designed to improve pharmaceutical manufacturing efficiency.
The enzymes may enable manufacturers to reduce solvent usage, raw material costs, downstream processing requirements, energy needs, and production cycles while maintaining high product quality and supporting sustainability objectives.
The enzyme systems enable the use of lower-impact solvents, reduce waste generation, and lower overall process energy requirements, supporting more environmentally responsible manufacturing practices.
The technology is particularly relevant for high-volume active pharmaceutical ingredients (APIs) and complex chiral compounds, where solvent usage and purification steps account for a substantial portion of manufacturing costs.
The company uses artificial intelligence and computational modeling tools to evaluate biochemical datasets, model structure-function relationships, and assess performance characteristics like stability and solvent compatibility, alongside traditional laboratory research.
Potential improvements include reduced solvent and material costs, improved reaction efficiency and conversion rates, lower energy and purification requirements, shorter production cycles, and enhanced scalability for commercial manufacturing.
The platform is designed for integration into existing production workflows, which may reduce the need for significant capital investment by pharmaceutical manufacturers.
All enzyme candidates remain subject to laboratory validation, scale-up testing, and applicable regulatory considerations, despite the use of AI and computational tools in development.
Vighnesh Dobale, Chief Executive Officer of Quantumzyme Corp., announced the breakthrough, stating it marks an important step forward in modernizing pharmaceutical manufacturing through advanced enzyme engineering.
The announcement was made on January 27, 2026, by Quantumzyme Corp. (OTC: QTZM), a biotransformation company based in San Diego, CA.
Curated from NewMediaWire
